

CITATION REPORT

List of articles citing

Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial

DOI: 10.1681/asn.2013010103

Journal of the American Society of Nephrology: JASN, 2014, 25, 175-86.

Source: <https://exaly.com/paper-pdf/58945416/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
204	Vitamin D receptor gene polymorphism and left ventricular hypertrophy in chronic kidney disease. 2014 , 6, 1029-37		31
203	The uses and abuses of Vitamin D compounds in chronic kidney disease-mineral bone disease (CKD-MBD). 2014 , 34, 660-8		18
202	Differences in cardiac structure assessed by echocardiography between renal transplant recipients and chronic kidney disease patients. 2014 , 46, 3194-8		7
201	Renal osteodystrophy in children: pathogenesis, diagnosis and treatment. 2014 , 26, 180-6		9
200	The use of fibroblast growth factor 23 testing in patients with kidney disease. 2014 , 9, 1283-303		44
199	The VITAH trial VITamin D supplementation and cardiac Autonomic tone in Hemodialysis: a blinded, randomized controlled trial. 2014 , 15, 129		7
198	The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study. 2014 , 15, 130		17
197	Chronic kidney disease [mineral bone disorder](CKD-MBD). 2015 , 10, 394-395		1
196	Effect of active vitamin D on cardiovascular outcomes in predialysis chronic kidney diseases: A systematic review and meta-analysis. 2015 , 20, 706-714		26
195	Vitamin D and Clinical Outcomes in Dialysis. 2015 , 28, 604-9		12
194	8.5 Ratschlage zur Abklung und Betreuung von Patienten mit chronischer Nierenerkrankung. 2015 ,		
193	Interplay of vitamin D, erythropoiesis, and the renin-angiotensin system. 2015 , 2015, 145828		51
192	Association of VDR gene polymorphisms with heart disease in chronic kidney disease patients. 2015 , 48, 1028-32		5
191	The Vitamin D Receptor Activator Maxacalcitol Provides Cardioprotective Effects in Diabetes Mellitus. 2015 , 29, 499-507		13
190	Vitamin D receptor agonist VS-105 improves cardiac function in the presence of enalapril in 5/6 nephrectomized rats. 2015 , 308, F309-19		11
189	Endocrine and metabolic changes affecting cardiovascular disease in dialysis patients. 2015 , 25, 223-5		5
188	Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference. 2015 , 87, 502-28		101

187	Vitamin D receptor polymorphism in chronic kidney disease patients with complicated cardiovascular disease. 2015 , 25, 187-93	9
186	[Native vitamin D in dialysis patients]. 2015 , 11, 5-15	4
185	Potential of vitamin D in treating diabetic cardiomyopathy. 2015 , 35, 269-79	23
184	Effect of oral vitamin D analogs on mortality and cardiovascular outcomes among adults with chronic kidney disease: a meta-analysis. 2015 , 8, 41-8	37
183	Influence of chronic kidney disease on cardiac structure and function. 2015 , 17, 581	18
182	Plasma 1,25-Dihydroxyvitamin D and the Risk of Developing Hypertension: The Prevention of Renal and Vascular End-Stage Disease Study. 2015 , 66, 563-70	24
181	Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia. 2015 , 66, 196-205	28
180	Effect of Vitamin D Supplementation on Blood Pressure: A Systematic Review and Meta-analysis Incorporating Individual Patient Data. 2015 , 175, 745-54	219
179	Vitamin D, the autonomic nervous system, and cardiovascular risk. 2015 , 3, e12349	10
178	Cardio-Renal Clinical Challenges. 2015 ,	1
177	Decreased Serum 25-hydroxyvitamin D Level Causes Interventricular Septal Hypertrophy in Patients on Peritoneal Dialysis: Cardiovascular Aspects of Endogenous Vitamin D Deficiency. 2016 , 2016, 2464953	
176	Role of vitamin D in diabetes mellitus and chronic kidney disease. 2016 , 7, 89-100	67
175	The VITAH Trial-Vitamin D Supplementation and Cardiac Autonomic Tone in Patients with End-Stage Kidney Disease on Hemodialysis: A Blinded, Randomized Controlled Trial. 2016 , 8,	5
174	Effect of Vitamin D Receptor Activators on Glomerular Filtration Rate: A Meta-Analysis and Systematic Review. 2016 , 11, e0147347	8
173	Optimal management of bone mineral disorders in chronic kidney disease and end stage renal disease. 2016 , 25, 120-6	14
172	Vitamin D in patients with chronic kidney disease: a position statement of the Working Group "Trace Elements and Mineral Metabolism" of the Italian Society of Nephrology. 2016 , 29, 305-328	22
171	Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification. 2016 , 17, 1363-73	12
170	Deficiency of Soluble Klotho as an Independent Cause of Uremic Cardiomyopathy. 2016 , 101, 311-30	9

169	Natural Vitamin D in Chronic Kidney Disease. 2016 , 465-491	
168	Which Vitamin D in Chronic Kidney Disease: Nutritional or Active Vitamin D? Or Both?. 2016 , 493-513	
167	Vitamin D Receptor and Interaction with DNA: From Physiology to Chronic Kidney Disease. 2016 , 75-116	2
166	Vitamin D and Heart Structure and Function in Chronic Kidney Disease. 2016 , 321-342	
165	Use of New Vitamin D Analogs in Chronic Kidney Disease. 2016 , 515-535	
164	CKD-Mineral Bone Disorder in Stage 4 and 5 CKD: What We Know Today?. 2016 , 23, 262-9	6
163	Cardiac effect of vitamin D receptor modulators in uremic rats. 2016 , 163, 20-7	6
162	Vitamin D receptor activator and prevention of cardiovascular events in hemodialysis patients Rationale and design of the Japan Dialysis Active Vitamin D (J-DAVID) trial. 2016 , 2,	3
161	Chronic kidney disease and cardiac morbidity What are the possible links?. 2016 , 41, 89-95	6
160	Epidemiology and Mechanisms of Uremia-Related Cardiovascular Disease. 2016 , 133, 518-36	108
159	Association of overhydration and cardiac dysfunction in patients have chronic kidney disease but not yet dialysis. 2016 , 12, 94-7	8
158	Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. 2016 , 48, 571-84	8
157	Research cardiac magnetic resonance imaging in end stage renal disease - incidence, significance and implications of unexpected incidental findings. 2017 , 27, 315-324	5
156	Mineral metabolism and cardiovascular disease in CKD. 2017 , 21, 53-63	32
155	Vitamin D Receptor Activator Use and Cause-specific Death among dialysis Patients: a Nationwide Cohort Study using Coarsened Exact Matching. 2017 , 7, 41170	12
154	Do the benefits of using calcitriol and other vitamin D receptor activators in patients with chronic kidney disease outweigh the harms?. 2017 , 22 Suppl 2, 51-56	11
153	Parathyroid hormone targets in chronic kidney disease and managing severe hyperparathyroidism. 2017 , 22 Suppl 2, 47-50	6
152	Effects of vitamin D or its analogues on the mortality of patients with chronic kidney disease: an updated systematic review and meta-analysis. 2017 , 71, 683-693	24

151	Oral paricalcitol: expanding therapeutic options for pediatric chronic kidney disease patients. 2017 , 32, 1103-1108	5
150	Vitamin D Deficiency and Supplementation in Cardiovascular Disorders. 2017 , 25, 189-196	9
149	KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). 2017 , 7, 1-59	675
148	Vitamin D receptor agonist VS-105 directly modulates parathyroid hormone expression in human parathyroid cells and in 5/6 nephrectomized rats. 2017 , 167, 48-54	3
147	Chronic kidney disease: KDIGO CKD-MBD guideline update: evolution in the face of uncertainty. 2017 , 13, 600-602	10
146	KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). 2017 , 70, 737-751	181
145	What Is the Role of Vitamin D Supplementation on Vascular Health in CKD?. 2017 , 12, 1377-1379	2
144	Vitamin D in the Spectrum of Prediabetes and Cardiovascular Autonomic Dysfunction. 2017 , 147, 1607-1615	11
143	Cholecalciferol, Calcitriol, and Vascular Function in CKD: A Randomized, Double-Blind Trial. 2017 , 12, 1438-1446	29
142	Treat secondary hyperparathyroidism in chronic kidney disease according to disease severity and trends in laboratory markers. 2017 , 33, 535-540	
141	Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease. 2017 , 12, 289-301	12
140	Vitamin D and Hypertension. 2017 , 15, 1-11	28
139	Role of Vitamin D in Uremic Vascular Calcification. 2017 , 2017, 2803579	21
138	Echokardiographische Befunde bei chronisch nierenkranken Patienten. 2018 , 13, 80-90	
137	Association of Pre-ESRD Serum Calcium With Post-ESRD Mortality Among Incident ESRD Patients: A Cohort Study. 2018 , 33, 1027-1036	10
136	[Chronic Kidney Disease - Update 2018]. 2018 , 143, 169-173	3
135	Summary of the 2018 ISN Frontiers Meeting: Kidney Disease and Cardiovascular Disease. 2018 , 3, 804-816	78
134	Hypercalcemic States Associated with Abnormalities of Vitamin D Metabolism. 2018 , 89-113	5

133	[Utilization of alfacalcidol and active vitamin D analogs in chronic kidney disease]. 2018 , 14, 189-200	3
132	Changes in renal function after discontinuation of vitamin D analogues in advanced chronic kidney disease. 2018 , 38, 179-189	0
131	Raising awareness on the therapeutic role of cholecalciferol in CKD: a multidisciplinary-based opinion. 2018 , 59, 242-259	10
130	Effects of paricalcitol on cardiovascular outcomes and renal function in patients with chronic kidney disease : A meta-analysis. 2018 , 43, 518-528	8
129	Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. 2018 , 168, 422-430	152
128	Update on Chronic Kidney Disease Mineral and Bone Disorder in Cardiovascular Disease. 2018 , 38, 542-558	16
127	Assessing the effect of oral activated vitamin D on overall survival in hemodialysis patients: a landmark analysis. 2018 , 19, 309	1
126	The Role of Vitamin D and Oxidative Stress in Chronic Kidney Disease. 2018 , 15,	8
125	Vitamin D Receptor Agonists for Patients Undergoing Hemodialysis. 2018 , 320, 2319-2321	2
124	Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis: The J-DAVID Randomized Clinical Trial. 2018 , 320, 2325-2334	36
123	CKD 5D Asia TM what is common and what is different from the West?. 2018 , 4,	
122	Renal association commentary on the KDIGO (2017) clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. 2018 , 19, 240	11
121	CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies. 2018 , 278, 49-59	74
120	Working Toward an Improved Understanding of Chronic Cardiorenal Syndrome Type 4. 2018 , 25, 454-467	2
119	Changes in renal function after discontinuation of vitamin D analogues in advanced chronic kidney disease. 2018 , 38, 179-189	
118	Making Policy in the Dark: The Use of Activated Vitamin D Under Bundled Payments for Dialysis Care. 2018 , 72, 161-163	
117	Personalized Management of Bone and Mineral Disorders and Precision Medicine in End-Stage Kidney Disease. 2018 , 38, 397-409	11
116	Impact of Vitamin D on the Cardiovascular System in Advanced Chronic Kidney Disease (CKD) and Dialysis Patients. 2018 , 10,	19

115	Effect of combined vitamin D receptor activator and lanthanum carbonate on serum fibroblast growth factor 23 level in predialysis patients (CVD-LAF study): design and method. 2018 , 22, 1309-1314	
114	Cardiac hypertrophy in chronic kidney disease: Role of Aldosterone and FGF23. 2018 , 4,	1
113	Vitamin D and Calcimimetics in Cardiovascular Disease. 2018 , 38, 251-266	13
112	Vitamin D Attenuates Endothelial Dysfunction in Uremic Rats and Maintains Human Endothelial Stability. 2018 , 7, e008776	13
111	Calcitriol and Analogs in the Treatment of Chronic Kidney Disease. 2018 , 471-484	
110	Prevalence and risk factors for hypercalcemia among non-dialysis patients with chronic kidney disease-mineral and bone disorder. 2018 , 50, 1871-1877	11
109	Vitamin D and Atherosclerotic Cardiovascular Disease. 2019 ,	20
108	Changes in microparticle profiles by vitamin D receptor activation in chronic kidney disease - a randomized trial. 2019 , 20, 290	4
107	Management of Secondary Hyperparathyroidism in Chronic Kidney Disease: A Focus on the Elderly. 2019 , 36, 885-895	6
106	Insuficiencia renal crónica. 2019 , 12, 4683-4692	
105	Evaluating extended-release calcifediol as a treatment option for chronic kidney disease-mineral and bone disorder (CKD-MBD). 2019 , 20, 2081-2093	6
104	Vitamin D and Health Outcomes: Then Came the Randomized Clinical Trials. 2019 , 322, 1866-1868	15
103	Pathogenesis and management of vascular calcification in CKD and dialysis patients. 2019 , 32, 553-561	15
102	Controversies in the Management of Secondary Hyperparathyroidism in Chronic Kidney Disease. 2019 , 17, 333-342	6
101	Resistin as a predictor of cardiovascular hospital admissions and renal deterioration in diabetic patients with chronic kidney disease. 2019 , 33, 107422	3
100	Active Vitamin D in Chronic Kidney Disease: Getting Right Back Where We Started from?. 2019 , 5, 59-68	11
99	Insight into the impact of vitamin D on cardiovascular outcomes in chronic kidney disease. 2019 , 24, 781-790	6
98	Vitamin D Supplementation and Cardiovascular Disease Risks in More Than 83 000 Individuals in 21 Randomized Clinical Trials: A Meta-analysis. 2019 , 4, 765-776	136

97	Vitamin D and Cardiovascular Complications of CKD: What's Next?. 2019 , 14, 932-934	10
96	Aiming Too Low: Reevaluation of Target Concentrations of Serum 25-Hydroxyvitamin D in Secondary Hyperparathyroidism. 2019 , 49, 281-283	2
95	Interaction between inflammation, mineral metabolism and the renin-angiotensin system: implications for cardiorenal outcomes in chronic kidney disease. 2019 , 34, 547-551	2
94	Impact of vitamin D on cardiac structure and function in chronic kidney disease patients with hypovitaminosis D: a randomized controlled trial and meta-analysis. 2021 , 7, 302-311	5
93	Updates in the management of heart failure for the chronic kidney disease patient. 2019 , 28, 262-266	4
92	Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Current Perspectives. 2019 , 12, 263-276	25
91	Mineral Bone Disorders in Chronic Kidney Disease. 2019 , 145-161.e6	
90	Vitamin D Disorders in Chronic Kidney Disease. 2019 , 162-175.e7	
89	Cardioprotective Effects of Paricalcitol Alone and in Combination With FGF23 Receptor Inhibition in Chronic Renal Failure: Experimental and Clinical Studies. 2019 , 32, 34-44	20
88	Vitamin D and cardiovascular disease in chronic kidney disease. 2019 , 34, 2509-2522	7
87	Dual Roles of the Mineral Metabolism Disorders Biomarkers in Prevalent Hemodialysis Patients: In Renal Bone Disease and in Vascular Calcification. 2019 , 38, 134-144	10
86	Stabilization of cell-cell junctions by active vitamin D ameliorates uraemia-induced loss of human endothelial barrier function. 2019 , 34, 252-264	13
85	Most exposed: the endothelium in chronic kidney disease. 2020 , 35, 1478-1487	18
84	Chronic Kidney Disease-Mineral and Bone Disorders. 2020 , 551-569	3
83	Chronic Kidney Disease. 2020 ,	1
82	The Interdisciplinary Clinic for Chronic Kidney Disease. 2020 , 921-935	
81	Management of Mineral and Bone Disorders in Chronic Kidney Disease. 2020 , 1013-1033	
80	Treatment of hyperphosphatemia: the dangers of aiming for normal PTH levels. 2020 , 35, 485-491	14

79	Nutritional vitamin D in CKD: Should we measure? Should we treat?. 2020 , 501, 186-197	10
78	Vitamin D levels condition the outcome benefits of renin-angiotensin system inhibitors (RASi) among patients undergoing percutaneous coronary intervention. 2020 , 160, 105158	2
77	Complications of metabolic acidosis and alkalinizing therapy in chronic kidney disease patients: a clinician-directed organ-specific primer. 2020 , 52, 2311-2320	1
76	Endothelial Dysfunction in Chronic Kidney Disease, from Biology to Clinical Outcomes: A 2020 Update. 2020 , 9,	50
75	Effect of vitamin D supplementation versus placebo on essential hypertension in patients with vitamin D deficiency: a double-blind randomized clinical trial. 2020 , 22, 1867-1873	5
74	Canadian Society of Nephrology Commentary on the Kidney Disease Improving Global Outcomes 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder. 2020 , 7, 2054358120944271	6
73	Testing Vitamin D Analogues for Vascular Calcification in Patients With CKD. 2020 , 2, 385-387	
72	Evidence in chronic kidney disease-mineral and bone disorder guidelines: is it time to treat or time to wait?. 2020 , 13, 513-521	13
71	Vitamin D in chronic kidney disease: is there a role outside of PTH control?. 2020 , 29, 243-247	2
70	Should We Consider the Cardiovascular System While Evaluating CKD-MBD?. 2020 , 12,	4
69	Active vitamin D is cardioprotective in experimental uraemia but not in children with CKD Stages 3-5. 2021 , 36, 442-451	3
68	The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation. 2021 , 36, 160-169	6
67	Klotho-independent actions of FGF23: targets, signal transduction, and cellular effects. 2021 , 65-77	
66	Effects of calcitriol and paricalcitol on renal fibrosis in CKD. 2021 , 36, 793-803	8
65	FGF23 and heart and vascular disease. 2021 , 133-156	
64	Chronic Kidney Disease [Mineral and Bone Disorder (CKD-MBD)]. 2021 , 1-29	
63	FGF23: resolved issues, remaining controversies, and future questions: a clinician's perspective. 2021 , 215-224	
62	Old and New Drugs for the Management of Bone Disorders in CKD. 2021 , 108, 486-495	4

61	Are Nutraceuticals Beneficial in Chronic Kidney Disease?. 2021 , 13,	3
60	Impact of nutritional vitamin D supplementation on parathyroid hormone and 25-hydroxyvitamin D levels in non-dialysis chronic kidney disease: a meta-analysis. 2021 , 14, 2177-2186	3
59	Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism: A Randomized Clinical Trial. 2021 , 16, 599-612	5
58	Muddying the waters of hyperparathyroidism management in chronic kidney disease: a brown tumour in a predialysis patient. 2021 , 51, 450-451	
57	Paricalcitol in management of chronic kidney disease—mineral and bone disorder. 2021 , 190-198	
56	Vitamin D Effects on Bone Homeostasis and Cardiovascular System in Patients with Chronic Kidney Disease and Renal Transplant Recipients. 2021 , 13,	4
55	Vitamin D Supplementation for Patients with Chronic Kidney Disease: A Systematic Review and Meta-analyses of Trials Investigating the Response to Supplementation and an Overview of Guidelines. 2021 , 109, 157-178	7
54	Key metalloproteinase-mediated pathways in the kidney. 2021 , 17, 513-527	8
53	Clinical Approach to Vascular Calcification in Patients With Non-dialysis Dependent Chronic Kidney Disease: Mineral-Bone Disorder-Related Aspects. 2021 , 8, 642718	3
52	Active vitamin D increases the risk of hypercalcaemia in non-dialysis chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis. 2021 , 14, 2437-2443	1
51	Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease. 2021 , 34, 1405-1418	5
50	Current treatment options for secondary hyperparathyroidism in patients with stage 3 to 4 chronic kidney disease and vitamin D deficiency. 2021 , 20, 1333-1349	1
49	Association between Vitamin D and Risk of Stroke: A PRISMA-Compliant Systematic Review and Meta-Analysis. 2021 , 84, 399-408	0
48	Biomarkers of heart and vascular lesions in the framework of mineral and bone disorders in chronic kidney disease, correction possibilities. 2021 , 99, 245-258	1
47	Paricalcitol as an Antiproteinuric Agent Can Result in the Deterioration of Renal and Heart Function in a Patient with Fabry Disease. 2017 , 18, 644-648	2
46	Differences in 25-Hydroxyvitamin D Clearance by eGFR and Race: A Pharmacokinetic Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 , 32, 188-198	12.7 6
45	Vitamin D and chronic kidney disease. 2014 , 29, 416-27	30
44	Vitamin D and Metabolic Diseases: Growing Roles of Vitamin D. 2018 , 27, 223-232	31

43 Vitamin D and Its Effects on the Heart. **2015**, 107-116

42 Vitamin D and heart: A not so sunny pathway. **2015**, 15, 751-2

41 Vitamin D and Progression of Renal Failure. **2016**, 249-265

40 CKD-MBD?????????????. **2018**, 51, 641-648

39 CKD-MBD?? (1) ; ???D?????????????????. **2018**, 51, 681-686

38 Does alfacalcidol reduce cardiovascular complications in hemodialysis patients?. **2019**, 7, 167

37 Chronic Kidney Disease, Common Comorbidities, and Diabetes. **2019**, 249-263

36 Chronic Kidney Disease-Mineral and Bone Disorder, Vitamin D Deficiency, and Secondary Hyperparathyroidism. **2020**, 141-151

35 Vitamin D in kidney disease. **2022**, 397-411

34 Renal osteodystrophy ¶update. **2020**, 133 (1), 37

33 KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention and Prevention of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Indian Commentary. **2020**, 30, 221-233

32 Pathophysiology of The Chronic Kidney Disease¶Mineral Bone Disorder. **2020**, 43-56

31 Low levels of Vitamin D an emerging risk for cardiovascular diseases: A review. **2017**, 11, 71-76 5

30 Characterization of Medication Trends for Chronic Kidney Disease: Mineral and Bone Disorder Treatment Using Electronic Health Record-Based Common Data Model. **2021**, 2021, 5504873 0

29 Chronic Kidney Disease ¶Mineral and Bone Disorder (CKD-MBD). **2021**, 109-121

28 CKD-MBD diagnosis: biochemical abnormalities.. **2021**, 43, 615-620

27 Real-World Assessment: Clinical Effectiveness and Safety of Extended-Release Calcifediol. **2021**, 52, 798-807 1

26 Relationship between selection of dosage forms of vitamin D receptor activators and short-term survival of patients on hemodialysis. **2021**, 43, 1528-1538

25	Cardiac valve calcification is associated with mortality in hemodialysis patients: a retrospective cohort study.. 2022 , 23, 43	1
24	Vitamin D receptor gene polymorphism predicts left ventricular hypertrophy in maintenance hemodialysis.. 2022 , 23, 32	0
23	Vitamin D Analogues and Fracture Risk in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. 2022 , 6, e10611	1
22	Interventions to Attenuate Vascular Calcification Progression in Chronic Kidney Disease: A Systematic Review of Clinical Trials.. <i>Journal of the American Society of Nephrology: JASN</i> , 2022 ,	12.7 5
21	CKD-MBD und sekundärer Hyperparathyreoidismus (Teil 2). 2021 , 25, 410-417	
20	Recomendaciones De La Sociedad Espanola De Nefrologia Para El Manejo De Las Alteraciones Del Metabolismo Oseo-Mineral En Los Pacientes Con Enfermedad Renal Cronica. 2021 (SEN-MM). 2022 ,	2
19	Vitamin D and Secondary Hyperparathyroidism in Chronic Kidney Disease: A Critical Appraisal of the Past, Present, and the Future. 2022 , 14, 3009	2
18	Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022s.	2
17	Vitamin D supplementation and risk of stroke: A meta-analysis of randomized controlled trials. 13,	1
16	Chronic Kidney Disease [Mineral and Bone Disorder (CKD-MBD). 2022 , 1751-1778	0
15	Effects of alfacalcidol on cardiovascular outcomes according to alkaline phosphatase levels in the J-DAVID trial. 2022 , 12,	0
14	Adherence to the Mediterranean Diet Is Associated with a More Favorable Left Ventricular Geometry in Patients with End-Stage Kidney Disease. 2022 , 11, 5746	1
13	Mechanism of calcitriol regulating parathyroid cells in secondary hyperparathyroidism. 13,	0
12	The 1,24,25(OH) ₃ D ₃ metabolite in clinical and experimental CKD: Impact of calcitriol treatment. 2022 , 106207	0
11	Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic. 2022 , 23, 12223	0
10	Effects of vitamin D3supplementation on cardiovascular and cancer outcomes by eGFR in VITAL. 10.34067/KID.000647	
9	Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients. 2022 , 23,	1
8	Chronic Kidney Disease-Mineral and Bone Disorder. 2022 , 589-616	0

- 7 Vitamin D und sekundärer Hyperparathyreoidismus (sHPT) bei CKD im Spiegel der Zeit. **2022**, 26, 448-452 ○
- 6 Effect of vitamin D receptor activators on cardiovascular events in patients on hemodialysis: a post hoc analysis of the LANDMARK study. ○
- 5 Disorders of Bone Mineral Metabolism in Chronic Kidney Disease. **2023**, 1631-1668 ○
- 4 Effect of active vitamin-D on left ventricular mass index: Results of a randomized controlled trial in type 2 diabetes and chronic kidney disease. **2023**, 261, 1-9 ○
- 3 Vitamin D and Chronic Kidney Disease Association with Mineral and Bone Disorder: An Appraisal of Tangled Guidelines. **2023**, 15, 1576 ○
- 2 Mineral and Bone Disorder in CKD. **2023**, 131-145 ○
- 1 Recommendations of the Spanish Society of Nephrology for the management of mineral and bone metabolism disorders in patients with chronic kidney disease: 2021 (SEN-MM). **2023**, ○